Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/6/2025

Management of Immune-Related Rash After Opdivo and Yervoy Treatment

Critical First Steps: Rule Out Life-Threatening Conditions

  • The American Society of Clinical Oncology (ASCO) recommends performing a thorough physical examination, including all mucosal surfaces, to assess for lymphadenopathy, facial/extremity swelling, pustules, blisters, erosions, and areas of dusky erythema painful to palpation 1
  • Obtain laboratory workup, including complete blood count with differential and liver function tests, to rule out DRESS syndrome, Stevens-Johnson syndrome, or toxic epidermal necrolysis 2, 4
  • Review biopsy results with dermatology to confirm immune-mediated dermatitis versus severe cutaneous adverse reactions (SCARs) 1

Grade-Based Treatment Algorithm

Grade 1: Rash <10% BSA

  • Continue immunotherapy without interruption, as recommended by the European Society for Medical Oncology (ESMO) 1, 2, 3
  • Apply topical emollients liberally multiple times daily, as suggested by the Journal of Clinical Oncology 1, 6
  • Use mild-to-moderate potency topical corticosteroids to affected areas once daily, as recommended by the American College of Dermatology 1, 2

Grade 2: Rash 10-30% BSA

  • Consider holding immunotherapy and monitor weekly, as recommended by the Journal of Clinical Oncology 1
  • Escalate to medium-to-high potency topical corticosteroids applied twice daily, as suggested by the Annals of Oncology 1, 2, 3
  • Continue topical emollients and oral antihistamines, as recommended by the ESMO 2, 3

Grade 3: Rash >30% BSA or Grade 2 with Severe Symptoms

  • Hold immunotherapy immediately until rash improves to Grade 1, as recommended by the ASCO 1, 2, 3, 4
  • Initiate systemic corticosteroids: oral prednisone 1 mg/kg/day, as suggested by the Journal of Clinical Oncology 1, 2, 3
  • Continue high-potency topical corticosteroids, oral antihistamines, and emollients, as recommended by the Annals of Oncology 1, 2, 4

Grade 4: Skin Sloughing >30% BSA with Systemic Symptoms

  • Immediately discontinue immunotherapy permanently, as recommended by the ASCO 1, 2, 3, 4
  • Admit patient urgently with direct oncology and dermatology involvement, as suggested by the Journal of Clinical Oncology 1, 2
  • Initiate IV methylprednisolone 1-2 mg/kg with slow tapering when toxicity resolves, as recommended by the Annals of Oncology 1, 2, 3

Monitoring and Follow-Up

  • Weekly monitoring for Grade 2 rash to assess for progression, as recommended by the Journal of Clinical Oncology 1, 2
  • Serial clinical photography to objectively track changes, as suggested by the Journal of Clinical Oncology 1
  • Watch for signs of secondary infection, which may require systemic antibiotics, as recommended by the Praxis Medical Insights 7